{"analyses":[{"ciNumSides":"TWO_SIDED","ciPctValue":"95","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.0006","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"89.13","upperLimit":"97.52","value":"94.3"},{"groupId":"OG001","lowerLimit":"73.38","upperLimit":"86.99","value":"80.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"141"},{"groupId":"OG001","value":"141"}],"units":"Participants"}],"description":"ORR, as assessed by IRC, is defined as number of participants who achieved a best overall response of complete remission (CR), complete remission with an incomplete marrow recovery (CRi), nodular partial remission (nPR) or partial remission (PR) at or before the initiation of subsequent anticancer therapy, disease progression or death, divided by the total number of participants randomized to each treatment arm.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pirtobrutinib 200 milligrams (mg) orally once daily in continuous 28-day cycles until disease progression or unacceptable toxicity.","id":"OG000","title":"Arm A - Pirtobrutinib"},{"description":"Participants received bendamustine 90 milligrams per square meter (mg/m²) intravenously on Days 1 and 2 of each 28-day cycle (Cycles 1-6) plus rituximab 375 mg/m² intravenously on Cycle 1 Day 1, then 500 mg/m² on Day 1 of Cycles 2-6. Eligible participants in Arm B crossed over to receive pirtobrutinib following independent review committee (IRC)-confirmed progressive disease (PD).","id":"OG001","title":"Arm B - Bendamustine Plus Rituximab"}],"paramType":"NUMBER","populationDescription":"All randomized participants.","reportingStatus":"POSTED","timeFrame":"From randomization until subsequent anticancer therapy, disease progression or death (up to 40 months)","title":"Arm A Compared to Arm B: Percentage of Participants With Overall Response (ORR), Assessed by IRC","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}